Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
about
The role of comfort and discomfort in insulin therapyDevelopment of oral immunomodulatory agents in the management of multiple sclerosisMental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjectsDeterminants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore studyPredictors of anxiety in multiple sclerosisCritical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyInitiating oral fingolimod treatment in patients with multiple sclerosisUsability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwaitRetrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis.Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.Which symptoms matter? Self-report and observer discrepancies in repressors and high-anxious women with metastatic breast cancer.In multiple sclerosis anxiety, not depression, is related to gender.Letter to the Editor: The Emerging Role of Pharmacists in the Multidisciplinary Care of Patients with Multiple Sclerosis.An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.Psychological Considerations and Interventions in Inflammatory Bowel Disease Patient Care.Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
P2860
Q27015671-B2DF8CBB-FA5C-478E-9315-20C12829BA87Q28388704-27D3B9A6-C247-49C1-ADE2-1480182DE01BQ30241221-3DCB6ABF-9652-4F79-BCCE-9228F9DE5181Q31038370-3661C186-11C9-46C0-B516-857AFB07C6F3Q33610126-75BCFCB3-57DF-4AD8-9694-011F1FBC81A1Q34293871-02D9067A-A93E-459B-811B-48F25C555BA8Q34714866-7A680770-78F3-40D3-B4C6-1A91537F0289Q35100869-A6AF00D6-28D0-4222-8A80-91E5D0EC3053Q35117418-5F566C8E-D3F3-4839-B5E8-8EB865C3341BQ35212994-C472A3B8-86B1-477B-9EC5-119103DCC30CQ35948187-0339E025-598F-4B3F-9AC5-55965A039DA1Q36999746-6EEB3DCE-FA61-48C8-AF98-A7416050B191Q37344587-C72E4E1C-F9A5-48BE-9DDD-2C758DDB6594Q37442166-248EB465-B1CB-4C00-BBD1-2C9314D4574DQ37501092-764DED9B-204E-4169-862C-985ED30D27BCQ37573148-E21733A0-32B3-4BDC-87C3-A12F45DBC2AAQ37702458-7DCE7D5F-9B5F-4909-8533-DD5E8F715EFCQ37706612-B3540836-B2FC-470D-9EE2-EADFCBAD5439Q37884071-6763735B-5190-489F-B34A-4796D7D68CF1Q38705140-5F0BC96F-2991-46FB-8E71-FAC33700BA70Q39533346-3DAD5DE8-22D7-4829-88EF-AF0DBBE6C775Q40871052-B9D72D1B-26A2-4CD6-B07B-A5D2A62ECCFCQ41626862-2FDEE737-8150-4E83-9C20-5F7A7CEA9643Q44175949-7D2D7A91-E4B4-4D72-9834-1E8574E9B785Q47570834-4928D4A5-3DC0-4354-B8DA-460BFD7AE92EQ48064606-1E9E97B8-7E28-495F-96EF-7E3088E8DFD0
P2860
Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@en
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@nl
type
label
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@en
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@nl
prefLabel
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@en
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@nl
P2093
P356
P1476
Injection anxiety remains a lo ...... herence in multiple sclerosis.
@en
P2093
Alicia P Sloan
Jodie K Haselkorn
Rhonda M Williams
P304
P356
10.1037/A0014460
P50
P577
2009-02-01T00:00:00Z